DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Review the data on ocular toxicity associated with the ADC, belantamab mafodotin, in this slideset from Clinical Care Options (CCO)

Paul G. Richardson, MD Released: November 12, 2021

Gain expert insights on managing ocular toxicity associated with ADCs in this slideset from Clinical Care Options (CCO)

Joann Kang, MD Released: November 12, 2021

Experts answer frequently asked questions on the management of relapsed or refractory multiple myeloma with BCMA-targeted agents, from a live Clinical Care Options (CCO) webinar

Sagar Lonial, MD
Program Director Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD Released: October 29, 2021